Lexicon (LXRX) Pharmaceuticals announced that Nasdaq’s listing qualifications staff has determined that the closing bid price of the Company’s common stock has been at $1.00 per share or greater for ten consecutive business days and that, accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). This update was previously disclosed in the Company’s Current Report on Form 8-K filed on July 28, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon Pharmaceuticals Regains Nasdaq Compliance
- Largest borrow rate increases among liquid names
- Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension
- Promising Outlook for Lexicon Pharmaceuticals’ Sotagliflozin in Type 1 Diabetes Management
- Lexicon announces post-hoc analysis of clinical data on sotagliflozin